Ribavirin with or without alpha interferon for chronic hepatitis C

L L Kjaergard; K Krogsgaard; C Gluud

doi:10.1002/14651858.CD002234

Ribavirin with or without alpha interferon for chronic hepatitis C

L L Kjaergard
, K Krogsgaard
, C Gluud

Copenhagen Trial Unit Rigshospitalet

20 Citationer (Scopus)

Abstract

Hepatitis C is a major cause of liver-related morbidity and mortality. Ribavirin plus interferon combination therapy is presently considered the optimal treatment of interferon naive patients with chronic hepatitis C, but its role in relapsers and non-responders to previous interferon therapy is not established.

Originalsprog	Engelsk
Tidsskrift	Cochrane Database of Systematic Reviews
Udgave nummer	2
Sider (fra-til)	CD002234
ISSN	1469-493X
DOI	https://doi.org/10.1002/14651858.CD002234
Status	Udgivet - 2002

Adgang til dokumentet

10.1002/14651858.CD002234

Citationsformater

@article{aa17e8eed1cc4811a61de810e30d3906,

title = "Ribavirin with or without alpha interferon for chronic hepatitis C",

abstract = "Hepatitis C is a major cause of liver-related morbidity and mortality. Ribavirin plus interferon combination therapy is presently considered the optimal treatment of interferon naive patients with chronic hepatitis C, but its role in relapsers and non-responders to previous interferon therapy is not established.",

keywords = "Antiviral Agents, Drug Therapy, Combination, Hepatitis C, Chronic, Humans, Interferon-alpha, Randomized Controlled Trials as Topic, Ribavirin",

author = "Kjaergard, \{L L\} and K Krogsgaard and C Gluud",

year = "2002",

doi = "10.1002/14651858.CD002234",

language = "English",

pages = "CD002234",

journal = "Cochrane Database of Systematic Reviews",

issn = "1469-493X",

publisher = "John Wiley and Sons Ltd",

number = "2",

}

TY - JOUR

T1 - Ribavirin with or without alpha interferon for chronic hepatitis C

AU - Kjaergard, L L

AU - Krogsgaard, K

AU - Gluud, C

PY - 2002

Y1 - 2002

N2 - Hepatitis C is a major cause of liver-related morbidity and mortality. Ribavirin plus interferon combination therapy is presently considered the optimal treatment of interferon naive patients with chronic hepatitis C, but its role in relapsers and non-responders to previous interferon therapy is not established.

AB - Hepatitis C is a major cause of liver-related morbidity and mortality. Ribavirin plus interferon combination therapy is presently considered the optimal treatment of interferon naive patients with chronic hepatitis C, but its role in relapsers and non-responders to previous interferon therapy is not established.

KW - Antiviral Agents

KW - Drug Therapy, Combination

KW - Hepatitis C, Chronic

KW - Humans

KW - Interferon-alpha

KW - Randomized Controlled Trials as Topic

KW - Ribavirin

U2 - 10.1002/14651858.CD002234

DO - 10.1002/14651858.CD002234

M3 - Journal article

C2 - 12076442

SN - 1469-493X

SP - CD002234

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 2

ER -

Ribavirin with or without alpha interferon for chronic hepatitis C

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater